IP Library Patent Application 17128195
Patent Application
App. No. 17/128,195

Treatment of cholestatic pruritus

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/128,195
Abstract

Treatment of cholestatic pruritus by therapy with seladelpar or a salt thereof.

Claims (22)

1 . A method of treating cholestatic pruritus associated with a hepatobiliary disease during treatment of the hepatobiliary disease by administering a therapeutically effective amount of seladelpar or a salt thereof.

2 . The method of claim 1 where the seladelpar or a salt thereof is a seladelpar L-lysine salt.

3 . The method of claim 2 where the seladelpar L-lysine salt is seladelpar L-lysine dihydrate salt.

4 . The method of claim 1 where the seladelpar or a salt thereof is administered orally.

5 . The method of claim 1 where the amount of seladelpar or a salt thereof is between 0.5 mg/day and 50 mg/day, when the amount is calculated as seladelpar.

6 .- 7 . (canceled)

8 . The method of claim 1 where the amount of seladelpar or a salt thereof is 2 mg/day, 5 mg/day, or 10 mg/day.

9 . (canceled)

10 . The method of claim 8 where the amount of seladelpar or a salt thereof is 5 mg/day.

11 . The method of claim 8 where the amount of seladelpar or a salt thereof is 10 mg/day.

12 . The method of claim 1 where the seladelpar or a salt thereof is administered once/day.

13 .- 14 . (canceled)

15 . The method of claim 1 where the hepatobiliary disease associated with the pruritus is a hepatocellular cholestasis.

16 . The method of claim 1 where the hepatobiliary disease associated with the pruritus is a cholangiocellular cholestasis.

17 . The method of claim 1 where the hepatobiliary disease associated with the pruritus is an obstructive cholestasis.

18 . The method of claim 1 where the hepatobiliary disease associated with the pruritus is an intrahepatic cholestatic disease.

19 . The method of claim 18 where the intrahepatic cholestatic disease is primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

20 . The method of claim 19 where the cholestatic pruritus is associated with primary biliary cholangitis.

21 . The method of claim 19 where the cholestatic pruritus is associated with primary sclerosing cholangitis.

22 . The method of claim 19 where the cholestatic pruritus is associated with progressive familial intrahepatic cholestasis.

23 . The method of claim 19 where the cholestatic pruritus is associated with Alagille syndrome.

24 . The method of claim 1 where the hepatobiliary disease associated with the pruritus is the intrahepatic cholestasis of pregnancy.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Oct 3, 2024
From: ABW CYCLOPS SPV LP
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 069833/0155 →